Company research
ENvue Medical, Inc.
CIK 1326706Updated Sep 27, 2026
SecurityFEED · OTC · equity
Historical securities (1)
FEED · NASDAQ · equity · closed Sep 14, 2026Name history
NanoVibronix, Inc. · through Dec 12, 2025Nano Vibronix, Inc. · through Mar 25, 2014Nano Vibronix Inc · through May 5, 2005
FEED price & chart
Loading TradingView…
OTC:FEED on TradingView ↗About the company
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
In the news
No coverage from other publishers is available.
Recent filings
EFFECT filing
8-K filing
10-Q filing
NT 10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 41,124,000Source | 3,629,000Source | 6,674,000Source | 5,879,000Source |
| Property, Plant and Equipment, NetUSD | 119,000Source | 9,000Source | 7,000Source | 7,000Source |
| GoodwillUSD | 29,082,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 4,380,000Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,224,000Source | — | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 289,000Source | 98,000Source | 318,000Source | 9,000Source |
| Inventory, NetUSD | 2,337,000Source | 2,191,000Source | 2,732,000Source | 2,175,000Source |
| Assets, CurrentUSD | 7,271,000Source | 3,331,000Source | 6,487,000Source | 5,609,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 290,000Source | 154,000Source | 712,000Source |
| Operating Lease, Right-of-Use AssetUSD | 127,000Source | 116,000Source | 5,000Source | 81,000Source |
| Other Assets, NoncurrentUSD | — | — | 1,000Source | 3,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 7,627,000Source | 3,002,000Source | 2,686,000Source | 2,646,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 3,000Source | 2,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 124,057,000Source | 70,505,000Source | 70,149,000Source | 65,634,000Source |
| Retained Earnings (Accumulated Deficit)USD | -90,481,000Source | -69,801,000Source | -66,096,000Source | -62,385,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -80,000Source | -80,000Source | -67,000Source | -18,000Source |
| Stockholders' Equity Attributable to ParentUSD | 33,497,000Source | 627,000Source | 3,988,000Source | 3,233,000Source |
| Liabilities and EquityUSD | 41,124,000Source | 3,629,000Source | 6,674,000Source | 5,879,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,660,000Source | 2,722,000Source | 2,454,000Source | 2,316,000Source |
| Operating Lease, Liability, CurrentUSD | 89,000Source | 52,000Source | 5,000Source | 81,000Source |
| Accounts Payable, CurrentUSD | 719,000Source | 47,000Source | 138,000Source | 66,000Source |
| Operating Lease, Liability, NoncurrentUSD | 28,000Source | 64,000Source | — | — |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 98,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 897,000Source | 1,000Source | 1,000Source | 1,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | 356,000Source | 293,000Source | 354,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 179,000Source | -221,000Source | 309,000Source | -191,000Source |
| Increase (Decrease) in InventoriesUSD | -249,000Source | -541,000Source | 557,000Source | 2,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | -373,000Source | -830,015Source | -1,267,000,000Source | -893,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,372,000Source | -2,516,000Source | -3,602,000Source | -7,035,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 88,000Source | -3,000Source | -1,000Source | -3,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 60,000Source | 3,000Source | 1,000Source | 3,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 12,786,000Source | 1,000Source | 4,222,000Source | 2,092,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 12,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 3,502,000Source | -2,531,000Source | 570,000Source | -5,024,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,254,000Source | 752,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 25,000Source | — | — | — |
| Income Taxes Paid, NetUSD | 52,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 356,000,000Source | 292,000,000Source | 354,000Source |
| Amortization of Intangible AssetsUSD | 855,000Source | — | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | -2,000Source | -16,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | -1,000Source | — | — |
| General and Administrative ExpenseUSD | 7,633,000Source | 3,461,000Source | 3,924,000Source | 3,931,000Source |
| GoodwillUSD | 29,082,000Source | — | — | — |
| Goodwill, Impairment LossUSD | 10,509,000Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 645,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | -645,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | -307,000Source | 19,000Source | 29,000Source | 35,000Source |
| Inventory Write-downUSD | 346,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -18,185,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -16,775,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Operating ExpensesUSD | 23,042,000Source | 5,090,000Source | 4,973,000Source | 5,179,000Source |
| Operating Lease, ExpenseUSD | — | 70,000Source | 70,000Source | 75,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 4,215,000Source | 2,090,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 1,300,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 102,000Source | — | 7,000Source | 2,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,553,000Source | 2,558,000Source | 2,283,000Source | 752,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Operating Income (Loss)USD | -22,889,000Source | -3,582,000Source | -3,436,000Source | -5,012,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -18,492,000Source | -3,686,000Source | -3,682,000Source | -5,413,000Source |
| Income Tax Expense (Benefit)USD | -307,000Source | 19,000Source | 29,000Source | 35,000Source |
| Net Income (Loss) Attributable to ParentUSD | -18,185,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Earnings Per Share, BasicUSD per share | -26.69Source | -13.73Source | -2.12Source | -3.84Source |
| Earnings Per Share, DilutedUSD per share | -26.69Source | -13.73Source | -2.12Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 628,534Source | 269,848Source | 1,750,109Source | 1,419,670Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 628,534Source | 269,848Source | 1,750,109Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 855,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | 66,000Source | 18,677Source | -25,000,000Source | 37,000Source |
| General and Administrative ExpenseUSD | 7,633,000Source | 3,461,000Source | 3,924,000Source | 3,931,000Source |
| Goodwill, Impairment LossUSD | 10,509,000Source | — | — | — |
| Gross ProfitUSD | 153,000Source | 1,508,000Source | 1,537,000Source | 167,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 18,713,000Source | 3,775,000Source | 3,785,000,000Source | 5,557,000Source |
| Interest ExpenseUSD | — | 135,000Source | 135,000Source | 347,000Source |
| Marketing and Advertising ExpenseUSD | — | 53,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -16,775,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Operating ExpensesUSD | 23,042,000Source | 5,090,000Source | 4,973,000Source | 5,179,000Source |
| Operating Lease, ExpenseUSD | — | 70,000Source | 70,000Source | 75,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | 399,000Source | — | — | — |
| Research and Development ExpenseUSD | 1,762,000Source | 909,000Source | 185,000Source | 283,000Source |
| Selling and Marketing ExpenseUSD | 2,493,000Source | 720,000Source | 864,000Source | 965,000Source |
Offerings
Registration 333-284973
- Gross proceeds
- 10000000.0
- Net proceeds
- 9300000.0
- Deal price
- 25.0
- Shares
- 400000
- Offering price
- $25
- Ticker
- NAOV
Filing attachments
ex99-1.htm · 8-K · 2025-12-12
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED’ New ticker symbol, “FEED” will begin trading on the Nasdaq at the open of the market on December 12, 2025 TYLER, Texas December 12, 2025 - ( BUSINESS WIRE ) - NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it will change its corporate n…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-19
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NanoVibronix Issues Letter to Shareholders ENvue® Feeding Tube Placement System Identified as Core Growth Platform Strategic Rebranding and Name Change to Reflect Company’s Focus on Multi-Billion-Dollar Enteral-Feeding Market The Company is Considering Strategic Alternatives for Legacy Assets TYLER, Texas, November 19, 2025 - ( BUSINESS WIRE ) - NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company spe…
Read attachment ↗ex4-1.htm · 8-K · 2025-09-17
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT NANOVIBRONIX, INC. Warrant ______ Initial Exercise Date: September 17, 2025 Shares: ────────────────────────────────────────────────────────────────────── THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, _____________ or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinaft…
Read attachment ↗ex99-1.htm · 8-K · 2025-09-17
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules TYLER, TX - September 16, 2025 - NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 291,204 shares of its commo…
Read attachment ↗ex99-1.htm · 8-K · 2025-08-08
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 NanoVibronix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on August 12, 2025 TYLER, TX, August 8, 2025 (Business Wire) - NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ra…
Read attachment ↗ex4-1.htm · 8-K · 2025-07-22
EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN…
Read attachment ↗